Drug Discovery

The $15 billion expansion of the Roche-Hansoh partnership signals a massive shift toward multi-program antibody-drug conjugate portfolios rather than traditional single-asset licensing deals. This momentous agreement, finalized in late 2026, represents a fundamental restructuring of how global

Regulatory hurdles and the complexity of characterizing nanoparticle behavior in humans have slowed the progress of bone-targeted nanomedicines. Despite these significant challenges, osteosarcoma remains a primary concern in pediatric oncology due to its high rate of metastasis and the persistent

Triple-negative breast cancer remains a significant therapeutic challenge due to its aggressive nature and the absence of common hormonal receptors. Because patients lack estrogen, progesterone, and HER2 receptors, standard endocrine therapies and HER2-targeted treatments are ineffective, leaving

Recent spectroscopy and microscopy data confirm that functionalized iron oxide particles can reach a final size of 317 nm after being loaded with chemotherapy drugs. This development marks a significant milestone in the quest to refine leukemia treatments, particularly in regions where traditional

While losartan appears to boost the activity of brown adipose tissue, concurrent research suggests that selective serotonin reuptake inhibitors may actually suppress this beneficial metabolic process. This dynamic highlights a critical intersection in modern pharmacology as of 2026, where

The landscape of modern oncology is rapidly shifting toward molecular precision, leaving behind the era of broad treatments that often fail to address specific genetic drivers. Patients with P-loop and alpha-C helix compressing mutations have long lacked targeted front-line options, often falling